Login / Signup

Combining AFM13, a Bispecific CD30/CD16 Antibody, with Cytokine-Activated Blood and Cord Blood-Derived NK Cells Facilitates CAR-like Responses Against CD30+ Malignancies.

Lucila N KerbauyNancy D MarinMecit KaplanPinaki P BanerjeeMelissa M Berrien-ElliottMichelle Becker-HapakRafet BasarMark FosterLuciana Garcia MeloCarly C NealEthan McClainMay DaherAna Karen Nunez CortesSweta DesaiFrancesca Wei Inng LimMayela Carolina MendtTimothy SchappeLi LiHila ShaimMayra ShanleyEmily L EnsleyNadima UpretyPamela WongEnli LiuSonny O AngRong CaiVandana NandivadaVakul MohantyQi MiaoYifei ShenNatalia BaranNatalie Wall FowlkesKen ChenLuis Muniz-FelicianoRichard E ChamplinYago L NietoJoachim KochMartin TrederWolfgang FischerOswaldo Keith OkamotoElizabeth J ShpallTodd A FehnigerKatayoun Rezvani
Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
We identify AFM13 as a promising combination with cytokine-activated adult blood or cord-blood NK cells to treat CD30+ hematologic malignancies, warranting clinical trials with these novel combinations.
Keyphrases
  • nk cells
  • cord blood
  • clinical trial
  • high speed
  • atomic force microscopy
  • mass spectrometry
  • young adults
  • high resolution
  • childhood cancer